Sleep pipeline expands as legacy drugs fund the trials
- The new sleep drug LUMRYZ reached 4,100 patients and generated $89.9 million in the third quarter of 2026.
- Third-quarter proprietary product sales hit $417.3 million, proving the ongoing strength of the commercial portfolio.
- Alkermes expanded its experimental orexin drug ALKS 7290 into a Phase 2 trial for Major Depressive Disorder.
- LYBALVI volume is growing through broader Medicare access, but price deductions will widen to 45% in 2027.
- The company carries heavy debt from the Avadel deal and is funding expensive trials for new orexin medicines.
A clearer path for the legacy portfolio
Alkermes is changing shape under new CEO Blair C. Jackson. It historically leaned on older brain medicines like LYBALVI, VIVITROL, and ARISTADA. After buying Avadel in early 2026, it added LUMRYZ, a once-at-bedtime oxybate for narcolepsy. This gave the company a real sleep medicine business before its experimental drug alixorexton reaches the market.
The bull case relies heavily on the legacy medicines funding the pipeline. Management confirmed that VIVITROL will not face an authorized generic in 2027. This removes a major near-term threat to cash flow. At the same time, LUMRYZ adoption accelerated to 4,100 patients in the third quarter of 2026, proving the Avadel acquisition is working.
The pipeline story is also getting wider. Alkermes is testing ALKS 7290 in adult ADHD and is expanding it into a 150-patient Phase 2 study for Major Depressive Disorder. The drug platform is growing, but the proof still has to come from larger clinical trials.
The bear case centers on costs, debt, and pricing pressure. Alkermes took on roughly $1.525 billion of debt for Avadel. The company must manage these interest payments while funding expensive Phase 3 alixorexton studies. Meanwhile, LYBALVI will face gross-to-net price deductions near 45% in 2027 as it enters more Medicare Part D plans.
Selling today, funding trials for tomorrow
Alkermes makes money mostly by selling its own medicines. In the third quarter of 2026, proprietary product sales were $417.3 million. VIVITROL contributed $127.6 million, ARISTADA family products added $103.9 million, LYBALVI generated $95.9 million, and LUMRYZ brought in $89.9 million.
The smaller revenue stream is manufacturing and royalty revenue. This line was $62.9 million in the third quarter of 2026. This segment continues a planned decline as older patents expire.
The model works if marketed products produce enough cash to pay debt service and fund clinical trials. LUMRYZ growth and the delay of generic VIVITROL help immensely. If LUMRYZ adoption stalls or trial costs spiral out of control, the company will have less financial flexibility.
The drugs that carry the story
LYBALVI
LYBALVI treats schizophrenia and bipolar I disorder. It produced Q3 2026 sales of $95.9 million and recently gained broad Medicare Part D access.
VIVITROL
VIVITROL is used for alcohol and opioid dependence. It had Q3 2026 sales of $127.6 million. Management does not expect an authorized generic to enter the market in 2027.
ARISTADA product family
ARISTADA and ARISTADA INITIO are long-acting schizophrenia medicines. The family had Q3 2026 sales of $103.9 million and provides steady cash flow.
LUMRYZ
LUMRYZ is a once-at-bedtime oxybate for narcolepsy. It added $89.9 million of sales in Q3 2026 and had roughly 4,100 patients on therapy exiting the quarter.
Alixorexton
Alixorexton is an orexin 2 receptor agonist in Phase 3 for narcolepsy type 1 and type 2. The Brilliance Studies are the central late-stage pipeline program.
ALKS 7290 and ALKS 4510
ALKS 7290 is in early trials for adult ADHD and Phase 2 for Major Depressive Disorder. ALKS 4510 is planned for studies in fatigue linked to multiple sclerosis and Parkinson's disease.
Product sales dominate the mix
The mix uses Q3 2026 revenue. Proprietary product sales were $417.3 million, while manufacturing and royalty revenues were $62.9 million.
What could break the thesis
Avadel debt load
High impact · Medium oddsAlkermes incurred about $1.525 billion of debt to finance the Avadel acquisition. That debt requires high interest payments and limits flexibility if product growth slows.
LYBALVI gross-to-net pressure
Medium impact · High oddsLYBALVI secured expanded Medicare Part D formulary access. This covers more patients but increases gross-to-net deductions, which are expected to hit 45% in 2027. This could limit net revenue growth.
Orexin pricing and market access
High impact · High oddsTakeda is expected to launch its orexin drug soon, which will set the market benchmark for pricing and insurance coverage. Alkermes will be a follower and must accept the ceiling Takeda establishes.
Orexin trials may not translate
High impact · Medium oddsAlixorexton is in Phase 3, and Alkermes is pushing ALKS 7290 into Major Depressive Disorder and ADHD. These areas are competitive, and early promise does not always become strong Phase 3 data.
Generic competition timing
High impact · Low oddsWhile management confirmed no authorized generic for VIVITROL in 2027, the exact timing of generic entry remains uncertain for the years following. A sudden launch would hit cash flows hard.
In one breath
What does Alkermes do?
Alkermes develops and sells medicines for brain and nervous system disorders. Its marketed products include LYBALVI, VIVITROL, ARISTADA, and LUMRYZ.
Why did Alkermes buy Avadel?
Avadel gave Alkermes LUMRYZ, an approved narcolepsy drug, plus a sleep medicine sales team. That helps Alkermes build a market presence before a possible future alixorexton launch.
What is the most important pipeline drug?
Alixorexton is the lead pipeline drug. It is an orexin 2 receptor agonist in Phase 3 studies for narcolepsy type 1 and type 2.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Alkermes plc in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

